

## Highlights of This Issue 1307

### SPECIAL FEATURES

#### CCR Translations

- 1309 **Next-Generation Medicine: Combining BCR-ABL and Hedgehog-Targeted Therapies**  
Kim-Hien T. Dao and Jeffrey W. Tyner  
*See article, p. 1422*
- 1312 **New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma**  
Riccardo Lencioni  
*See article, p. 1503*

#### CCR Perspectives in Drug Approval

- 1315 **Is the European Pediatric Medicine Regulation Working for Children and Adolescents with Cancer?**  
Gilles Vassal, Birgit Georger, and Bruce Morland

#### Statistics in CCR

- 1326 **Borrowing Information across Subgroups in Phase II Trials: Is It Useful?**  
Boris Freidlin and Edward L. Korn

#### CCR Drug Updates

- 1335 **Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer**  
Jean Hoffman-Censits and Wm. Kevin Kelly

#### Molecular Pathways

- 1340 **Molecular Pathways: Toll-like Receptors in the Tumor Microenvironment—Poor Prognosis or New Therapeutic Opportunity**  
Lisa A. Ridnour, Robert Y.S. Cheng, Christopher H. Switzer, Julie L. Heinecke, Stefan Ambs, Sharon Glynn, Howard A. Young, Giorgio Trinchieri, and David A. Wink
- 1347 **Molecular Pathways: Hepatitis C Virus, CXCL10, and the Inflammatory Road to Liver Cancer**  
Jessica Brownell and Stephen J. Polyak

## HUMAN CANCER BIOLOGY

- 1353 **Murine Microenvironment Metaprofiles Associate with Human Cancer Etiology and Intrinsic Subtypes**  
David H. Nguyen, Erik Fredlund, Wei Zhao, Charles M. Perou, Allan Balmain, Jian-Hua Mao, and Mary Helen Barcellos-Hoff
- 1363 **PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction**  
Kaoru Abiko, Masaki Mandai, Junzo Hamanishi, Yumiko Yoshioka, Noriomi Matsumura, Tsukasa Baba, Ken Yamaguchi, Ryusuke Murakami, Ayaka Yamamoto, Budiman Kharma, Kenzo Kosaka, and Ikuo Konishi
- 1375 **Rab25 Regulates Invasion and Metastasis in Head and Neck Cancer**  
Panomwat Amornphimoltham, Kamil Rechache, Jamie Thompson, Andrius Masedunskas, Kantima Leelahavanichkul, Vyomesh Patel, Alfredo Molinolo, J. Silvio Gutkind, and Roberto Weigert
- 1389 **MicroRNA-200a Promotes Anoikis Resistance and Metastasis by Targeting YAP1 in Human Breast Cancer**  
San-Jian Yu, Jing-Ying Hu, Xia-Ying Kuang, Jian-Min Luo, Yi-Feng Hou, Gen-Hong Di, Jiong Wu, Zhen-Zhou Shen, Hou-Yan Song, and Zhi-Ming Shao
- 1400 **HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification**  
Jianghua Zheng, Jinglong Wang, Xueqing Sun, Mingang Hao, Tao Ding, Dan Xiong, Xiumin Wang, Yu Zhu, Gang Xiao, Guangcun Cheng, Meizhong Zhao, Jian Zhang, and Jianhua Wang
- 1411 **Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer**  
Sally J. Davis, Karen E. Sheppard, Richard B. Pearson, Ian G. Campbell, Kylie L. Gorringer, and Kaylene J. Simpson

---

**CANCER THERAPY: PRECLINICAL**

- 1422 **Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1-Positive Leukemia**  
Seiichiro Katagiri, Tetsuzo Tauchi, Seiichi Okabe, Yosuke Minami, Shinya Kimura, Taira Maekawa, Tomoki Naoe, and Kazuma Ohyashiki  
*See commentary, p. 1309*
- 1433 **Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition**  
Ying Zhang, Kaitlyn E. Farenholtz, Yanzhi Yang, Fadila Guessous, Charles G. diPierro, Valerie S. Calvert, Jianghong Deng, David Schiff, Wenjun Xin, Jae K. Lee, Benjamin Purow, James Christensen, Emanuel Petricoin, and Roger Abounader
- 1445 **Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB**  
Lorenz Bastian, Jana Hof, Madlen Pfau, Iduna Fichtner, Cornelia Eckert, Günter Henze, Javier Prada, Arend von Stackelberg, Karl Seeger, and Shabnam Shalpour
- 1458 **Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide**  
Eric I. Zimmerman, Shuiying Hu, Justin L. Roberts, Alice A. Gibson, Shelley J. Orwick, Lie Li, Alex Sparreboom, and Sharyn D. Baker
- 1467 **Human Regulatory T Cells Do Not Suppress the Antitumor Immunity in the Bone Marrow: A Role for Bone Marrow Stromal Cells in Neutralizing Regulatory T Cells**  
Teun Guichelaar, Maarten E. Emmelot, Henk Rozemuller, Bianka Martini, Richard W.J. Groen, Gert Storm, Henk M. Lokhorst, Anton C. Martens, and Tuna Mutis
- 1476 **Effective Anti-Neu-Initiated Antitumor Responses Require the Complex Role of CD4<sup>+</sup> T Cells**  
Eric D. Mortenson, SaeGwang Park, Zhujun Jiang, Shengdian Wang, and Yang-Xin Fu

**IMAGING, DIAGNOSIS, PROGNOSIS**

- 1487 **<sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography in the Management of Patients with Thymic Epithelial Tumors**  
Anish Thomas, Esther Mena, Karen Kurdziel, David Venzon, Sean Khozin, Arlene W. Berman, Peter Choyke, Eva Szabo, Arun Rajan, and Giuseppe Giaccone
- 1494 **Molecular Photoacoustic Imaging of Follicular Thyroid Carcinoma**  
Jelena Levi, Sri-Rajashekar Kothapalli, Sarah Bohndiek, Joon-Kee Yoon, Anca Dragulescu-Andrasi, Carsten Nielsen, Aleksandra Tisma, Sunil Bodapati, Gayatri Gowrishankar, Xinrui Yan, Carmel Chan, Daniela Starcevic, and Sanjiv Sam Gambhir
- 1503 **Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization**  
Beom Kyung Kim, Seung Up Kim, Myeong-Jin Kim, Kyung Ah Kim, Do Young Kim, Jun Yong Park, Sang Hoon Ahn, Kwang-Hyub Han, and Chae Yoon Chon  
*See commentary, p. 1312*

**CANCER THERAPY: CLINICAL**

- 1512 **Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors**  
Anne F. Schott, Melissa D. Landis, Gabriela Dontu, Kent A. Griffith, Rachel M. Layman, Ian Krop, Lacey A. Paskett, Helen Wong, Lacey E. Dobrolecki, Michael T. Lewis, Amber M. Froehlich, Jaya Paraniham, Daniel F. Hayes, Max S. Wicha, and Jenny C. Chang
- 1525 **Targeting of <sup>111</sup>In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells**  
Erik H.J.G. Aarntzen, Mangala Srinivas, Fernando Bonetto, Luis J. Cruz, Pauline Verdijk, Gerty Schreibelt, Mandy van de Rakt, W. Joost Lesterhuis, Maichel van Riel, Cornelius J.A. Punt, Gosse J. Adema, Arend Heerschap, Carl G. Figdor, Wim J. Oyen, and I. Jolanda M. de Vries

- 1534 **Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization**  
Ruben Niesvizky, Tomer M. Mark, Maureen Ward, David S. Jayabalan, Roger N. Pearse, Megan Manco, Jessica Stern, Paul J. Christos, Lena Mathews, Tsiporah B. Shore, Faiza Zafar, Karen Pekle, Zhaoying Xiang, Scott Ely, Donna Skerret, Selina Chen-Kiang, Morton Coleman, and Maureen E. Lane
- 1547 **Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer**  
Firas L. T. Al-Ubaidi, Niklas Schultz, Olga Loseva, Lars Egevad, Torvald Granfors, and Thomas Helleday
- 1557 **Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study**  
Andrew X. Zhu, Marek Ancukiewicz, Jeffrey G. Supko, Dushyant V. Sahani, Lawrence S. Blaszkowsky, Jeffrey A. Meyerhardt, Thomas A. Abrams, Nadine Jackson McCleary, Pankaj Bhargava, Alona Muzikansky, Susan Sheehan, Eileen Regan, Eamala Vasudev, Michelle Knowles, Charles S. Fuchs, David P. Ryan, Rakesh K. Jain, and Dan G. Duda
- 1567 **Phase I Study of GRN1005 in Recurrent Malignant Glioma**  
Jan Drappatz, Andrew Brenner, Eric T. Wong, April Eichler, David Schiff, Morris D. Groves, Tom Mikkelsen, Steve Rosenfeld, John Sarantopoulos, Christina A. Meyers, Robert M. Fielding, Kelly Elian, Xiaolin Wang, Betty Lawrence, Mona Shing, Stephen Kelsey, Jean Paul Castaigne, and Patrick Y. Wen
- 1587 **Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer**  
Christine E. Horak, Lajos Pusztai, Guan Xing, Ovidiu C. Trifan, Cristina Saura, Ling-Ming Tseng, Stephen Chan, Rosanne Welcher, and David Liu
- 1596 **Establishment and Validation of Circulating Tumor Cell-Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients**  
Antonio Giordano, Brian L. Egleston, David Hajage, Joseph Bland, Gabriel N. Hortobagyi, James M. Reuben, Jean-Yves Pierga, Massimo Cristofanilli, and Francois-Clement Bidard
- 1603 **CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC**  
Rathi N. Pillai, Seth A. Brodie, Gabriel L. Sica, You Shaojin, Ge Li, Dana C. Nickleach, Liu Yuan, Vijay A. Varma, Dacian Bonta, James G. Herman, Malcom V. Brock, Maria J.A. Ribeiro, Suresh S. Ramalingam, Taofeek K. Owonikoko, Fadlo R. Khuri, and Johann C. Brandes
- 1612 **A Single Nucleotide Polymorphism in Inflammatory Gene *RNASEL* Predicts Outcome after Radiation Therapy for Localized Prostate Cancer**  
Jonathan D. Schoenfeld, Danielle N. Margalit, Julie L. Kasperzyk, Irene M. Shui, Jennifer R. Rider, Mara M. Epstein, Allison Meisner, Stacey A. Kenfield, Neil E. Martin, Paul L. Nguyen, Philip W. Kantoff, Edward L. Giovannucci, Meir J. Stampfer, and Lorelei A. Mucci
- 1620 **Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin-Containing Chemotherapy**  
Leslie Mortland, Todd A. Alonzo, Roland B. Walter, Robert B. Gerbing, Amit K. Mitra, Jessica A. Pollard, Michael R. Loken, Betsy Hirsch, Susana Raimondi, Janet Franklin, Stanley Pounds, Xueyuan Cao, Jeffrey E. Rubnitz, Raul C. Ribeiro, Alan Gamis, Soheil Meshinchi, and Jatinder K. Lamba


## PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

- 1577 **A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non-Small Cell Lung Cancer Patients**  
Hao Tang, Guanghua Xiao, Carmen Behrens, Joan Schiller, Jeffrey Allen, Chi-Wan Chow, Milind Suraokar, Alejandro Corvalan, Jianhua Mao, Michael A. White, Ignacio I. Wistuba, John D. Minna, and Yang Xie

---

## ABOUT THE COVER

The microphotograph shows the induction of apoptosis after combined treatment with bortezomib and the histone deacetylase inhibitor valproic acid in a xenograft mouse model of acute lymphoblastic leukemia (ALL). Human B-cell precursor ALL cells were injected subcutaneously into nonobese diabetic/severe combined immunodeficient mice. Tumor sections after treatments were stained with mAbs against human CD10 (red) indicating leukemia cells, cleaved caspase-3 (green) indicating apoptotic cells, and 4',6-diamidino-2-phenylindole (nuclei, blue). For details, please see the article by Bastian and colleagues on page 1445 of this issue.



# Clinical Cancer Research

**19 (6)**

*Clin Cancer Res* 2013;19:1307-1627.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/19/6>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/19/6>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.